Sara Toffanin
Overview
Explore the profile of Sara Toffanin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taouli B, Hoshida Y, Kakite S, Chen X, Tan P, Sun X, et al.
Eur Radiol
. 2017 Apr;
27(11):4472-4481.
PMID: 28439654
Objectives: In this preliminary study, we examined whether imaging-based phenotypes are associated with reported predictive gene signatures in hepatocellular carcinoma (HCC). Methods: Thirty-eight patients (M/F 30/8, mean age 61 years)...
2.
Hernandez-Gea V, Toffanin S, Friedman S, Llovet J
Gastroenterology
. 2013 Jan;
144(3):512-27.
PMID: 23313965
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third greatest cause of cancer-related death worldwide, and its incidence is increasing. Despite the significant improvement in management...
3.
Toffanin S, Cornella H, Harrington A, Llovet J
Hepatology
. 2012 Nov;
56(5):1998-2000.
PMID: 23115011
No abstract available.
4.
Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al.
Gastroenterology
. 2012 Sep;
143(6):1660-1669.e7.
PMID: 22974708
Background & Aims: The Notch signaling pathway is activated in leukemia and solid tumors (such as lung cancer), but little is known about its role in liver cancer. Methods: The...
5.
Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, et al.
Clin Cancer Res
. 2012 Jul;
18(18):4997-5007.
PMID: 22811581
Purpose: Hepatocellular carcinoma (HCC) is a heterogeneous cancer with active Wnt signaling. Underlying biologic mechanisms remain unclear and no drug targeting this pathway has been approved to date. We aimed...
6.
Wang P, Xu M, Toffanin S, Li Y, Llovet J, Russell D
Proc Natl Acad Sci U S A
. 2012 Jun;
109(28):11264-9.
PMID: 22733778
The distinct phenotypic and prognostic subclasses of human hepatocellular carcinoma (HCC) are difficult to reproduce in animal experiments. Here we have used in vivo gene targeting to insert an enhancer-promoter...
7.
Toffanin S, Sia D, Villanueva A
J Hepatol
. 2012 Jun;
57(3):490-1.
PMID: 22691573
No abstract available.
8.
Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al.
J Hepatol
. 2012 Feb;
56(6):1343-50.
PMID: 22322234
Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent...
9.
Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, et al.
J Hepatol
. 2011 Jun;
55(6):1325-31.
PMID: 21703203
Background & Aims: Vascular invasion is a major predictor of tumor recurrence after surgical treatments for hepatocellular carcinoma (HCC). While macroscopic vascular invasion can be detected by radiological techniques, pre-operative...
10.
Toffanin S, Alsinet C, Cornella H, Sia D, Llovet J
Gastroenterology
. 2011 Apr;
140(7):2138-40.
PMID: 21515272
No abstract available.